These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9251329)

  • 21. Liposomal amphotericin B.
    Sundar S
    Lancet; 2001 Mar; 357(9258):801-2. PubMed ID: 11253992
    [No Abstract]   [Full Text] [Related]  

  • 22. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visceral leishmaniasis treated with liposomal amphotericin B.
    Catania S; Aiassa C; Tzahtzoglou S; Catania N; Tucciarone L; Antimi A; Ragni G; Clerico A
    Pediatr Infect Dis J; 1999 Jan; 18(1):73-4. PubMed ID: 9951989
    [No Abstract]   [Full Text] [Related]  

  • 25. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
    Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
    Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient.
    Alsina-Gibert M; López-Lerma I; Martinez-Chamorro E; Herrero-Mateu C
    Arch Dermatol; 2006 Jun; 142(6):787-9. PubMed ID: 16785393
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
    Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
    Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
    BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy for visceral leishmaniasis.
    van Griensven J; Boelaert M
    Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
    [No Abstract]   [Full Text] [Related]  

  • 35. Liposomes as drug delivery system in leishmaniasis.
    Kshirsagar NA; Gokhale PC; Pandya SK
    J Assoc Physicians India; 1995 Jan; 43(1):46-8. PubMed ID: 9282640
    [No Abstract]   [Full Text] [Related]  

  • 36. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis.
    Castagnola E; Davidson RN; Fiore P; Tasso L; Rossi G; Mangraviti S; Di Martino L; Scotti S; Cascio A; Pempinello R; Gradoni L; Giacchino R
    Trans R Soc Trop Med Hyg; 1996; 90(3):317-8. PubMed ID: 8758092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphotericin B regulates the host immune response in visceral leishmaniasis: reciprocal regulation of protein kinase C isoforms.
    Mukherjee AK; Gupta G; Bhattacharjee S; Guha SK; Majumder S; Adhikari A; Bhattachrya P; Majumdar SB; Majumdar S
    J Infect; 2010 Jul; 61(2):173-84. PubMed ID: 20546775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different liposomal amphotericin B formulations for visceral leishmaniasis.
    Dorlo TP; Balasegaram M
    Lancet Glob Health; 2014 Aug; 2(8):e449. PubMed ID: 25103515
    [No Abstract]   [Full Text] [Related]  

  • 40. Single-dose liposomal amphotericin B for visceral leishmaniasis.
    Kshirsagar NA
    Lancet Glob Health; 2014 Apr; 2(4):e203. PubMed ID: 25103058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.